Department of Neurosurgery, Neurological Institute, Taipei Veterans General Hospital, Taipei, Taiwan.
School of Medicine, National Yang-Ming University, Taipei, Taiwan.
Neuroendocrinology. 2020;110(11-12):977-987. doi: 10.1159/000505332. Epub 2019 Dec 11.
Acromegaly is so rare that its natural history, including incidence, risk of cancers, and mortality rates, remains elusive. This natural study utilized a nationwide database to provide a better understanding of acromegaly's disease course.
A cohort of 1,195 acromegaly patients were identified and followed-up from 1997 to 2013. Incidence, operation, and re-operation rates were calculated. Excessive mortality and cancer risk related to acromegaly were estimated by standardized mortality ratio (SMR) and standardized incidence ratio (SIR).
The incidence was 2.78 per million-person-years, with little gender predominance (female vs. male, 49.5 vs. 50.5%, respectively). There was female predominance only among 50 and 60 year-olds (incidence rate ratio: 1.37 and 1.43, p < 0.001 and p = 0.002). Among them, 673 (56.3%) had hypophysectomy surgery, and the young-onset (<40 years) patients had more re-operations (15.5%, p = 0.01). The overall mortality rate was 22.3 per 1,000 person-years, with a median survival of 4.67 years (with no gender differences, p = 0.38). The overall SMR of acromegaly patients was 1.41, and the onset-age-specific SMRs of the early- and middle-onset patients were higher than for those with late-onset. There were 87 newly diagnosed cancers in the cohort, with an incidence rate of 10.6 per 1,000 person-years (median 5.4 years). The overall SIR of cancers was 1.91, and there were no differences among gender, onset-age, and disease duration (all SIR >1, approximately 2).
Acromegaly is associated with an excessive risk of mortality and two-fold higher risk of cancers. Patients with acromegaly should be managed appropriately after the diagnosis.
肢端肥大症非常罕见,其自然病史,包括发病率、癌症风险和死亡率,仍然难以捉摸。本项自然研究利用全国性数据库,更好地了解肢端肥大症的病程。
本研究纳入了 1997 年至 2013 年间的 1195 例肢端肥大症患者,并对其进行随访。计算发病率、手术和再次手术的比例。通过标准化死亡率比(SMR)和标准化发病比(SIR)评估与肢端肥大症相关的过度死亡率和癌症风险。
发病率为 2.78/百万人年,性别差异不大(女性与男性分别为 49.5%和 50.5%)。仅在 50 岁和 60 岁的患者中存在女性优势(发病率比:1.37 和 1.43,p < 0.001 和 p = 0.002)。其中 673 例(56.3%)患者接受了垂体切除术,且发病年龄较轻(<40 岁)的患者有更多的再次手术(15.5%,p = 0.01)。总的死亡率为 22.3/1000 人年,中位生存时间为 4.67 年(无性别差异,p = 0.38)。肢端肥大症患者的总 SMR 为 1.41,早、中年发病患者的 SMR 高于晚发病患者。该队列中共有 87 例新发癌症,发病率为 10.6/1000 人年(中位发病时间为 5.4 年)。癌症的总 SIR 为 1.91,性别、发病年龄和疾病持续时间之间无差异(所有 SIR >1,约为 2)。
肢端肥大症与死亡率升高及癌症风险增加两倍相关。确诊后应适当管理肢端肥大症患者。